Article Details

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in ...

Retrieved on: 2023-12-08 22:16:56

Tags for this article:

Click the tags to see associated articles and topics

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in .... View article details on hiswai:

Excerpt

... Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today posi.

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up